Search Results

Strategy: From Personal Pain to Scientific Purpose Dr. pain research at Hopkins and later an MD-PhD at Mount Sinai. Pain became more than biology — it became a personal strategy. “Half the time, in pain, what works in vivo doesn’t translate to clinic. by AI ________ About Alex Serafini Alex was born and raised in the Bay Area and received his BS/MS Neuroscience

published seminal papers where he used various approaches to describe the role of opioid receptors in pain Dr Gendron is co-director of the FRQS-funded Quebec Pain Research Network and the Editor-in-Chief in Louis Gendron on the web Université de Sherbrooke Neurosciences Sherbrooke RQRD Pubmed Google Scholar

.” – Ben Clements His pivot into neuroscience and pharmacology during grad school at the University of “We’re enhancing the powerful pain-relieving effects of opioids while limiting respiratory depression He is particularly excited by the novel application of PAMs in chronic and neuropathic pain models , Discovering breakthrough results in neuroma pain models via a spontaneous collaboration. and mechanisms of allostery, as well as efficacy studies in mouse and rat models of acute and chronic pain

Only available for AGPCR 24 Attendees Authors & Affiliations "Tolias, Kimberley F., Departments of Neuroscience Houston, TX 77030" About Joseph Duman "Joseph Duman is an Assistant Professor in the Department of Neuroscience Biochemistry and Genetics at the University of Sheffield followed up by obtaining a PhD in molecular neuroscience at the Sheffield Institute for Translational Neuroscience. My main topics were protein biochemistry, Drosophila husbandry, and genetics.

. 🧠 Pain, inflammation, metabolism: the implications go far beyond signaling bias. 🔗 Read the full This could reshape how we understand CGRP-related physiology—and how we target it in drug design. 🧠 Pain

Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at Klein's lab where she helped to investigate the role of various ATP-sensitive potassium channels in pain

Then I moved to the University of Oxford on a 4-year Wellcome Trust Scholarship in Neuroscience, through which I gained an M.Sc. from Somerville College and a D.Phil. from Magdalen College Oxford, both in Neuroscience.

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics breakthrough GPCR research career The inside story behind founding Blue Therapeutics and targeting supraspinal pain Woolf at Boston Children’s Hospital and Harvard Medical School, where he deepened his understanding of pain Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics , a biotech startup focused on targeting supraspinal GPCRs for chronic pain.

Home → Flash News → Can we preserve opioid pain relief without the side effects? GPCR Podcast Can we preserve opioid pain relief without the side effects?

Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany);

She then pursued her Ph.D. in neuroscience at Cambridge University. Marshall is the VP Head of Neuroscience Discovery and Head of Discovery UK, Global Head of Neuroscience

AGPCRs in the periphery The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN inflammation Gabriela Aust The CELSR/ADGRC Homolog Flamingo Is Not Autoproteolytically Processed By The GAIN Neuroscience (Oxford, UK); 2005-2009: D.Phil. Neuroscience (Oxford, UK); 2009-2016: Group leader, Institute of Neurophysiology (Würzburg, Germany); We found that the knock-out of cupidon induces a gain in cell adhesion and cell fusion, resembling the

He also directs a collaborative neuroscience R&D program with Servier (France) and is the co-founder Prior to joining Heptares, Chris was a neuroscience researcher at GlaxoSmithKline, UK (1998-2009). Chris serves on the editorial boards of the British Journal of Pharmacology, ACS Chemical Neuroscience

GPCR Title: Characterization of Novel Opioid-Neurotensin Bifunctional Ligands Designed to Target Pain interested in characterizing novel G protein-coupled receptors (GPCRs) ligands for the treatment of chronic pain

Nigel Bunnett at the NYU Pain Research Center as a postdoctoral researcher. focuses on investigating GPCR signaling and trafficking in the context of inflammation and chronic pain Next Steps Badr will continue focusing his research on GPCRs involved in pain and inflammation during Badr shared his passion for GPCR signalling and regulation, specifically in the context of pain and inflammation

of opioid receptors and is currently focusing on the pharmacology of cannabinoids in the context of pain

Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia

GAIN-targeted antibodies, and cancer-associated mutations at the GAIN-7TM interface, alter holoreceptor Neuroscience Institute, Institute for Biophysical Dynamics, and Center for Mechanical Excitability, The Instituto Politécnico Nacional (Cinvestav-IPN), México City, México. 3 Sorbonne Université, Inserm, CNRS, Neurosciences Mariam, originally from Armenia, completed her bachelor's degree in Neuroscience at American University in Washington, DC and her dual-title PhD in Neuroscience and Clinical and Translational Sciences at

Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry and Neuroscience In particular, D2R is the main pharmacological target of antipsychotic drugs prescribed for schizophrenia

characterization of the pharmacological properties of cannabinoids in conjunction with terpenes for pain

coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience

Integrating GPCR biology, behavioral pharmacology, and systems neuroscience approaches, the Slosky Lab trainer for the University of Minnesota's MS and Ph.D. programs in Pharmacology, Graduate Program in Neuroscience

conjugates to target GPCRs, with a focus on receptors relevant for treating osteoporosis, diabetes, and pain

a special thought for Marc Caron (1946-2022) to commemorate his great contributions to the GPCR and Neurosciences include also world-class and diverse GPCR scientists working in the arenas of structure and signaling, neuroscience

Engelenburg1, Joost Smolders1,3, and Jörg Hamann1,2 1Department of Neuroimmunology, Netherlands Institute for Neuroscience Postdoctoral researcher, Amsterdam UMC; 2019-2022: Senior postdoctoral researcher, Netherlands Institute for Neuroscience

He finished his career as Head of Bioinformatics for Neuroscience and working on the GSKs novel genetics

Full Agenda Session V Structural mechanisms of AGPCR signaling and function Structural Determinants Of GAIN Unveiling the GPS Cleavage Mechanism in ADGRL1 with QM/MM Florian Seufert Structural Determinants Of GAIN ADGRs are autoproteo-lytically cleaved at the GPCR proteolysis site (GPS), an HXS/T motif within the GAIN We de-termined the crystal structure of the human ADGRB2/BAI2 hormone receptor (HormR) and GAIN domains Richard C.*, and Araç, Demet* Department of Biochemistry and Molecular Biology, The University of Chicago Neuroscience

next career step took her to AstraZeneca as a postdoctoral trainee, where she studied animal models of pain

neurons), Vollum Institute Portland (visiting scientist with Ed McCleskey, sensory neuron properties); Pain

Vanderbilt University before continuing her training as a postdoctoral fellow at the Vanderbilt Center for Neuroscience